{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:54:13Z","timestamp":1794243253846,"version":"4.9.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFC2706100"],"award-info":[{"award-number":["2023YFC2706100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01790-x","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:05:14Z","timestamp":1775671514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial"],"prefix":"10.1186","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct04737850","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Runhui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenge","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runzi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"1790_CR1","doi-asserted-by":"crossref","unstructured":"Working Group of Chinese Guideline for the Diagnosis and Treatment of Childhood Primary Immune Thrombocytopenia; Subspecialty Group of Hematologic Diseases, Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics. Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021). Pediatr Investig. 2022;6(2):63\u201374.","DOI":"10.1002\/ped4.12305"},{"issue":"22","key":"1790_CR2","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780\u2013817.","journal-title":"Blood Adv"},{"key":"1790_CR3","doi-asserted-by":"crossref","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"1790_CR4","doi-asserted-by":"crossref","unstructured":"Al-Jadiry M, Ghali H, Aref I, et al. PB2301: PEDIATRIC IMMUNE THROMBOCYTOPENIA; A GLANCE AT PATIENTS AND CURRENT THERAPEUTIC CHALLENGES. HemaSphere 6(Suppl) 2020.","DOI":"10.1097\/01.HS9.0000852032.39405.0f"},{"issue":"5","key":"1790_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1067\/S0022-3476(03)00535-3","volume":"143","author":"T K\u00fchne","year":"2003","unstructured":"K\u00fchne T, Buchanan GR, Zimmerman S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003;143(5):605\u20138.","journal-title":"J Pediatr"},{"issue":"23","key":"1790_CR6","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829\u201366.","journal-title":"Blood Adv"},{"issue":"13","key":"1790_CR7","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/bloodadvances.2023012541","volume":"8","author":"CE Neunert","year":"2024","unstructured":"Neunert CE, Arnold DM, Grace RF, et al. The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia. Blood Adv. 2024;8(13):3578\u201382.","journal-title":"Blood Adv"},{"issue":"10039","key":"1790_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","volume":"388","author":"MD Tarantino","year":"2016","unstructured":"Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45\u201354.","journal-title":"Lancet"},{"key":"1790_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720912992","volume":"11","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Grace RF, Kuter DJ. The role of Romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020;11:2040620720912992.","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"1790_CR10","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","volume":"2","author":"JB Bussel","year":"2015","unstructured":"Bussel JB, de Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315\u201325.","journal-title":"Lancet Haematol"},{"issue":"19","key":"1790_CR11","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1182\/bloodadvances.2020004110","volume":"5","author":"X Cheng","year":"2021","unstructured":"Cheng X, Fu L, Ma J, et al. Spotlight on Eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice. Blood Adv. 2021;5(19):3799\u2013806.","journal-title":"Blood Adv"},{"issue":"1","key":"1790_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/09537104.2020.1847267","volume":"33","author":"X Liu","year":"2022","unstructured":"Liu X, Hou M, Li J, et al. Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study. Platelets. 2022;33(1):82\u20138.","journal-title":"Platelets"},{"key":"1790_CR13","doi-asserted-by":"crossref","unstructured":"Grace RF, Leblebisatan G, Aydinok Y, et al. Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study. Lancet Haematol. 2025.","DOI":"10.1016\/S2352-3026(25)00107-3"},{"issue":"12","key":"1790_CR14","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1182\/bloodadvances.2019000279","volume":"3","author":"CE Neunert","year":"2019","unstructured":"Neunert CE, Rose MJ. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice. Blood Adv. 2019;3(12):1907\u201315.","journal-title":"Blood Adv"},{"key":"1790_CR15","doi-asserted-by":"crossref","unstructured":"Zhang P, Miao WJAoPM. Eltrombopag-induced liver dysfunction during the treatment of immune thrombocytopenia and its risk factors. 2021;10(6):6419-24","DOI":"10.21037\/apm-21-1067"},{"issue":"11","key":"1790_CR16","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1111\/jcmm.13809","volume":"22","author":"C Xie","year":"2018","unstructured":"Xie C, Zhao H, Bao X, et al. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. J Cell Mol Med. 2018;22(11):5367\u201377.","journal-title":"J Cell Mol Med"},{"issue":"13","key":"1790_CR17","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Hetrombopag: first approval. Drugs. 2021;81(13):1581\u20135.","journal-title":"Drugs"},{"issue":"1","key":"1790_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01047-9","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Liu X, Li Y, et al. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol. 2021;14(1):37.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1790_CR19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/jth.15602","volume":"20","author":"H Mei","year":"2022","unstructured":"Mei H, Liu X, Li Y, et al. Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: results from an open-label extension study. J Thromb Haemost. 2022;20(3):716\u201328.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1790_CR20","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s00277-024-05826-5","volume":"103","author":"H Mei","year":"2024","unstructured":"Mei H, Liu X, Li Y, et al. Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial. Ann Hematol. 2024;103(7):2273\u201381.","journal-title":"Ann Hematol"},{"key":"1790_CR21","unstructured":"Working Group of Chinese Guideline for the Diagnosis and Treatment of Childhood Primary Immune Thrombocytopenia; Subspecialty Group of Hematologic Diseases, Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics. Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021). Zhonghua er ke za zhi = Chinese Journal Pediatr. 2021;59(10):810\u20139."},{"issue":"10004","key":"1790_CR22","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","volume":"386","author":"JD Grainger","year":"2015","unstructured":"Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649\u201358.","journal-title":"Lancet"},{"issue":"4","key":"1790_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/jth.12524","volume":"12","author":"J Peng","year":"2014","unstructured":"Peng J, Ma SH, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12(4):497\u2013504.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1790_CR24","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.1016\/S2352-3026(25)00107-3","volume":"12","author":"RF Grace","year":"2025","unstructured":"Grace RF, Leblebisatan G, Aydinok Y, et al. Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study. Lancet Haematol. 2025;12(7):e494\u2013504.","journal-title":"Lancet Haematol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01790-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01790-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01790-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:27:31Z","timestamp":1775741251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01790-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1790"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01790-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with Declaration of Helsinki principles. All procedures were approved by the ethics committee review board of each participating hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.L., J.X., and Z.Z. are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd.; the remaining authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}